letters & comments

NHC Submits Comments on FDA’s Draft Guidance for Voluntary Incorporation of Patient Preference Information

12/05/2024 Read More

Community Support Letter for the Rare Pediatric Disease PRV Program

12/04/2024 Read More

NHC Comments on Patient Priorities for the Lame Duck

12/02/2024 Read More

NHC Comments on CMS 2026 Notice of Benefit and Payment Parameters

11/12/2024 Read More

NHC Comments on Landmark FDA Guidance for Diversity in Clinical Trials

09/26/2024 Read More

NHC Comments on Centers for Medicare & Medicaid Services (CMS) in response to the proposed rule Medicare and Medicaid Programs: Calendar Year 2025 Payment Policies under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies

09/09/2024 Read More

NHC Comments on Centers for Medicare & Medicaid Services (CMS) in response to the CY 2025 OPPS proposed rule

09/09/2024 Read More

NHC Comments on Negotiation Data Elements and Drug Price Negotiation Process for Initial Price Applicability Year 2027 under Sections 11001 and 11002 of the IRA ICR Forms

09/03/2024 Read More

NHC Comments on Framework for Discussion on Reforming the NIH

08/16/2024 Read More
« Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19